LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Ocular Therapeutix Inc

Fermé

SecteurSoins de santé

7.19 0.28

Résumé

Variation du prix de l'action

24h

Actuel

Min

7.17

Max

7.34

Chiffres clés

By Trading Economics

Revenu

-16M

-64M

Ventes

-6.4M

11M

BPA

-0.372

Marge bénéficiaire

-602.342

Employés

274

EBITDA

-20M

-64M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+143.21% upside

Dividendes

By Dow Jones

Prochains Résultats

5 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-147M

1.2B

Ouverture précédente

6.91

Clôture précédente

7.19

Sentiment de l'Actualité

By Acuity

60%

40%

319 / 382 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

Ocular Therapeutix Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

16 mai 2025, 19:39 UTC

Principaux Mouvements du Marché

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

17 mai 2025, 17:15 UTC

Actualités

Trump Attacks Walmart for Tariff-Related Price Increases -- WSJ

17 mai 2025, 09:30 UTC

Actualités
Résultats

In a Trade War, Walmart Lacks Some of Amazon's Ammunition -- Heard on the Street -- WSJ

17 mai 2025, 08:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 mai 2025, 08:20 UTC

Market Talk
Résultats

Financial Services Roundup: Market Talk

16 mai 2025, 23:18 UTC

Actualités

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 mai 2025, 22:30 UTC

Actualités

U.S. Loses Last Triple-A Credit Rating -- Update

16 mai 2025, 21:56 UTC

Market Talk

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 mai 2025, 21:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 mai 2025, 21:54 UTC

Actualités

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 mai 2025, 21:22 UTC

Market Talk

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 mai 2025, 21:17 UTC

Market Talk

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 mai 2025, 21:17 UTC

Actualités

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 mai 2025, 21:05 UTC

Market Talk

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 mai 2025, 20:55 UTC

Acquisitions, Fusions, Rachats

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mai 2025, 20:50 UTC

Market Talk
Résultats

Financial Services Roundup: Market Talk

16 mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 mai 2025, 20:37 UTC

Actualités

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 mai 2025, 20:33 UTC

Market Talk
Acquisitions, Fusions, Rachats

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 mai 2025, 20:30 UTC

Acquisitions, Fusions, Rachats

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 mai 2025, 20:18 UTC

Actualités

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 mai 2025, 20:16 UTC

Actualités

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 mai 2025, 20:15 UTC

Résultats

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 mai 2025, 20:11 UTC

Acquisitions, Fusions, Rachats

Henry Schein: William K. Daniel Joins Board

16 mai 2025, 20:10 UTC

Acquisitions, Fusions, Rachats

Henry Schein: Strategic Investment by KKR Completed

16 mai 2025, 20:05 UTC

Acquisitions, Fusions, Rachats

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mai 2025, 19:38 UTC

Market Talk

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16 mai 2025, 19:07 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

16 mai 2025, 18:51 UTC

Actualités

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16 mai 2025, 18:41 UTC

Acquisitions, Fusions, Rachats

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

Comparaison

Variation de prix

Ocular Therapeutix Inc prévision

Objectif de Prix

By TipRanks

143.21% hausse

Prévisions sur 12 Mois

Moyen 17.56 USD  143.21%

Haut 22 USD

Bas 14 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

10 ratings

10

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

6.97 / 7.62Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

319 / 382Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.